Why the study?
Does dexrazoxane prevent anthracycline-induced cardiotoxicity in patients receiving chemotherapy?
Population
Patients receiving chemotherapy, specifically including breast cancer and pediatric sarcoma patients…
Design
Review
Authors
Loading...
May support dexrazoxane for anthracycline cardiotoxicity prevention in breast cancer; leaves open broader validation across regimens and populations.
Does dexrazoxane prevent anthracycline-induced cardiotoxicity in patients receiving chemotherapy?
Dexrazoxane effectively prevents cumulative anthracycline-induced cardiomyopathy without compromising oncologic response rates.
Höchster et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: